MicroRNA-26a regulates insulin sensitivity and metabolism of glucose and lipids

Journal of Clinical Investigation

Volumn 125, Issue 6, 2015, Pages 2497-2509

  Fu, Xianghui ^a,b   Dong, Bingning ^c   Tian, Yan ^a,b   Lefebvre, Philippe ^d,e,f,g   Meng, Zhipeng ^b   Wang, Xichun ^b   Pattou, François ^d,f   Han, Weidong ^b   Wang, Xiaoqiong ^b   Lou, Fang ^b   Jove, Richard ^b   Staels, Bart ^d,e,f,g   Moore, David D ^c   Huang, Wendong ^b  

^a SICHUAN UNIVERSITY   (China)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIV LILLE   (France)

^e INSERM   (France)

^f France   (France)

^g INSTITUT PASTEUR DE LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CRE RECOMBINASE; GLUCOSE; GLYCOGEN; INSULIN; LIPID; MICRORNA 26A; TRIACYLGLYCEROL; FAT INTAKE; FATTY ACID; MICRORNA; MIRN26 MICRORNA, MOUSE; MIRN26A MICRORNA, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; BROWN ADIPOSE TISSUE; CHOLESTEROL LIVER LEVEL; CHOLESTEROL METABOLISM; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; FATTY ACID METABOLISM; FATTY ACID SYNTHESIS; GENE ONTOLOGY; GENOTYPE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; GLYCOGEN METABOLISM; HOMEOSTATIC MODEL ASSESSMENT INDEX OF INSULIN RESISTANCE; HUMAN; HUMAN TISSUE; INSULIN RELEASE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; LIPID DIET; LIPID METABOLISM; LIPID STORAGE; LIVER CARCINOGENESIS; LIVER CELL; LIVER METABOLISM; MASS SPECTROMETRY; METABOLIC PARAMETERS; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SUBCUTANEOUS FAT; TRIACYLGLYCEROL BLOOD LEVEL; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; UPREGULATION; ADVERSE EFFECTS; ANIMAL; CHEMICALLY INDUCED; CLINICAL TRIAL; DISEASE MODEL; DRUG EFFECTS; FAT INTAKE; FEMALE; GENETICS; INSULIN RESISTANCE; LIVER; MALE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY; PHARMACOLOGY; TRANSGENIC MOUSE;

ANIMALS; DIABETES MELLITUS, TYPE 2; DIETARY FATS; DISEASE MODELS, ANIMAL; FATTY ACIDS; FEMALE; GLUCOSE; HUMANS; INSULIN; INSULIN RESISTANCE; LIVER; MALE; MICE; MICE, TRANSGENIC; MICRORNAS; OBESITY; SIGNAL TRANSDUCTION;

EID: 84930405027     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI75438     Document Type: Article

References (43)

1. Copps KD, White MF. Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2. 2565-2582.
2. Patel S, Doble BW, MacAulay K, Sinclair EM, Drucker DJ, Woodgett JR. Tissue-specific role of glycogen synthase kinase 3beta in glucose homeostasis and insulin action. Mol Cell Biol. 2008;28(20): 6314-6328.
3. Samuel VT, Shulman GI. Mechanisms for insulin resistance: Common threads and missing links. Cell. 2012;148(5): 852-871.
4. Moore DD. Nuclear receptors reverse McGarry's vicious cycle to insulin resistance. Cell Metab. 2012;15(5): 615-622.
5. Bu SY, Mashek MT, Mashek DG. Suppression of long chain acyl-CoA synthetase 3 decreases hepatic de novo fatty acid synthesis through decreased transcriptional activity. J Biol Chem. 2009;284(44): 30474-30483.
6. Westerbacka J, et al. Genes involved in fatty acid partitioning and binding, lipolysis, monocyte/ macrophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin-resistant subjects. Diabetes. 2007;56(11): 2759-2765.
7. Lin HV, Accili D. Hormonal regulation of hepatic glucose production in health and disease. Cell Metab. 2011;14(1): 9-19.
8. Beale EG, Hammer RE, Antoine B, Forest C. Disregulated glyceroneogenesis: PCK1 as a candidate diabetes and obesity gene. Trends Endocrinol Metab. 2004;15(3): 129-135.
9. Gomez-Valades AG, et al. Pck1 gene silencing in the liver improves glycemia control, insulin sensitivity, and dyslipidemia in db/db mice. Diabetes. 2008;57(8): 2199-2210.
10. Boj SF, et al. Diabetes risk gene and Wnt effector Tcf7l2/TCF4 controls hepatic response to perinatal and adult metabolic demand. Cell. 2012;151(7): 1595-1607.
11. Ward PS, Thompson CB. Metabolic reprogramming: A cancer hallmark even warburg did not anticipate. Cancer Cell. 2012;21(3): 297-308.
12. Doria A, Patti ME, Kahn CR. The emerging genetic architecture of type 2 diabetes. Cell Metab. 2008;8(3): 186-200.
13. Voight BF, et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet. 2010;42(7): 579-589.
14. Rottiers V, Naar AM. MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol. 2012;13(4): 239-250.
15. Lujambio A, Lowe SW. The microcosmos of cancer. Nature. 2012;482(7385): 347-355.
16. Quiat D, Olson EN. MicroRNAs in cardiovascular disease: From pathogenesis to prevention and treatment. J Clin Invest. 2013;123(1): 11-18.
17. Esau C, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 2006;3(2): 87-98.
18. Trajkovski M, et al. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature. 2011;474(7353): 649-653.
19. Jordan SD, et al. Obesity-induced overexpression of miRNA-143 inhibits insulin-stimulated AKT activation and impairs glucose metabolism. Nat Cell Biol. 2011;13(4): 434-446.
20. Kornfeld JW, et al. Obesity-induced overexpression of miR-802 impairs glucose metabolism through silencing of Hnf1b. Nature. 2013;494(7435): 111-115.
21. Ji J, et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med. 2009;361(15): 1437-1447.
22. Kota J, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell. 2009;137(6): 1005-1017.
23. Dill H, Linder B, Fehr A, Fischer U. Intronic miR-26b controls neuronal differentiation by repressing its host transcript, ctdsp2. Genes Dev. 2012;26(1): 25-30.
24. Fu X, et al. miR-26a enhances miRNA biogenesis by targeting Lin28B and Zcchc11 to suppress tumor growth and metastasis. Oncogene. 2014;33(34): 4296-4306.
25. Meng Z, et al. miR-194 is a marker of hepatic epithelial cells and suppresses metastasis of liver cancer cells in mice. Hepatology. 2010;52(6): 2148-2157.
26. Siomi H, Siomi MC. Posttranscriptional regulation of microRNA biogenesis in animals. Mol Cell. 2010;38(3): 323-332.
27. Fu X, et al. MicroRNA-26a targets ten eleven translocation enzymes and is regulated during pancreatic cell differentiation. Proc Natl Acad Sci U S A. 2013;110(44): 17892-17897.
28. Postic C, et al. Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic β cell-specific gene knock-outs using Cre recombinase. J Biol Chem. 1999;274(1): 305-315.
29. Huang da W, Sherman BT, Lempicki RA. Sys- tematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1): 44-57.
30. Bernardo BC, et al. Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function. Proc Natl Acad Sci U S A. 2012;109(43): 17615-17620.
31. Rottiers V, et al. Pharmacological inhibition of a microRNA family in nonhuman primates by a seed-targeting 8-mer antimiR. Sci Transl Med. 2013;5(212): 212ra162.
32. Ellis JM, Frahm JL, Li LO, Coleman RA. Acylcoenzyme A synthetases in metabolic control. Curr Opin Lipidol. 2010;21(3): 212-217.
33. Johnson AM, Olefsky JM. The origins and drivers of insulin resistance. Cell. 2013;152(4): 673-684.
34. Newgard CB. Interplay between lipids and branched-chain amino acids in development of insulin resistance. Cell Metab. 2012;15(5): 606-614.
35. Bezy O, et al. PKC? regulates hepatic insulin sensitivity and hepatosteatosis in mice and humans. J Clin Invest. 2011;121(6): 2504-2517.
36. Tahrani AA, Bailey CJ, Del Prato S, Barnett AH. Management of type 2 diabetes: New and future developments in treatment. Lancet. 2011;378(9786): 182-197.
37. van Rooij E, Olson EN. MicroRNA therapeutics for cardiovascular disease: Opportunities and obstacles. Nat Rev Drug Discov. 2012;11(11): 860-872.
38. Janssen HL, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med. 2013;368(18): 1685-1694.
39. Fu X, et al. miR-26a enhances miRNA biogenesis by targeting Lin28B and Zcchc11 to suppress tumor growth and metastasis. Oncogene. 2014;33(34): 4296-4306.
40. Badeanlou L, Furlan-Freguia C, Yang G, Ruf W, Samad F. Tissue factor-protease-Activated receptor 2 signaling promotes diet-induced obesity and adipose inflammation. Nat Med. 2011;17(11): 1490-1497.
41. Dong B, et al. Activation of nuclear receptor CAR ameliorates diabetes and fatty liver disease. Proc Natl Acad Sci U S A. 2009;106(44): 18831-18836.
42. Zhou Y, et al. Regulation of glucose homeostasis through a XBP-1-FoxO1 interaction. Nat Med. 2011;17(3): 356-365.
43. Chen WD, et al. Neonatal activation of the nuclear receptor CAR results in epigenetic memory and permanent change of drug metabolism in mouse liver. Hepatology. 2012;56(4): 1499-1509.